These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 17113759

  • 1. A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression.
    Vanelle JM, Douki S.
    Eur Psychiatry; 2006 Dec; 21(8):523-30. PubMed ID: 17113759
    [Abstract] [Full Text] [Related]

  • 2. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia.
    Mortimer A, Martin S, Lôo H, Peuskens J, SOLIANOL Sudy Group.
    Int Clin Psychopharmacol; 2004 Mar; 19(2):63-9. PubMed ID: 15076013
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial.
    Kim SW, Shin IS, Kim JM, Lee SH, Lee JH, Yoon BH, Yang SJ, Hwang MY, Yoon JS.
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct 01; 31(7):1504-9. PubMed ID: 17692448
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine.
    Hofer A, Rettenbacher MA, Edlinger M, Huber R, Bodner T, Kemmler G, Sachs G, Fleischhacker WW.
    Pharmacopsychiatry; 2007 Jan 01; 40(1):1-8. PubMed ID: 17327953
    [Abstract] [Full Text] [Related]

  • 10. Augmentation treatment with amisulpride in schizophrenic patients partially responsive to olanzapine.
    Molina JD, Toledo-Romero F, López-Rodríguez E, Amorin-Díaz M, Lerma-Carrillo I, López-Muñoz F.
    Pharmacopsychiatry; 2011 Jun 01; 44(4):142-7. PubMed ID: 21710404
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Fluphenazine (oral) versus atypical antipsychotics for schizophrenia.
    Sampford JR, Sampson S, Li BG, Zhao S, Xia J, Furtado VA.
    Cochrane Database Syst Rev; 2016 Jul 02; 7(7):CD010832. PubMed ID: 27370402
    [Abstract] [Full Text] [Related]

  • 14. Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology.
    Kotler M, Strous RD, Reznik I, Shwartz S, Weizman A, Spivak B.
    Int Clin Psychopharmacol; 2004 Jan 02; 19(1):23-6. PubMed ID: 15101566
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.
    Tollefson GD, Sanger TM, Lu Y, Thieme ME.
    Arch Gen Psychiatry; 1998 Mar 02; 55(3):250-8. PubMed ID: 9510219
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.